## Management of Invasive Amebic Colitis **Key Point:** Demonstration of trophozoites with ingested RBCs in stool is diagnostic of invasive amebic dysentery (E. histolytica), regardless of serology status. Negative serology does NOT exclude invasive disease—serologic tests may take 7–10 days to become positive during acute invasive infection. ### Why Immediate Treatment is Indicated The presence of **hematophagous trophozoites** (RBC-containing amoebae) is pathognomonic for tissue invasion and requires urgent antimicrobial therapy: **High-Yield:** Metronidazole is the first-line agent for invasive amebic disease (colitis, liver abscess). Standard dosing: 750 mg TDS × 10 days. ### Two-Drug Regimen for Intestinal Amebiasis | Drug | Indication | Dosing | Rationale | |------|-----------|--------|----------| | Metronidazole | Invasive disease (tissue trophozoites) | 750 mg TDS × 10 days | Kills trophozoites in mucosa and submucosa | | Paromomycin | Luminal cysts (asymptomatic carriers, post-treatment) | 25–35 mg/kg/day ÷ 3 doses × 7 days | Eliminates cysts to prevent relapse and transmission | **Clinical Pearl:** Metronidazole alone leaves 10–40% of patients with persistent luminal infection; paromomycin as a second agent reduces relapse risk to <5%. ### Why Serology Negativity Does NOT Delay Treatment 1. **Early invasive disease** may present before antibodies develop (first 7–10 days) 2. **Acute colitis** shows lower seropositivity (~70%) compared to liver abscess (>90%) 3. **Delaying treatment** while awaiting serology conversion risks perforation, toxic megacolon, and sepsis **Mnemonic:** **METRO-PAROMO** = Metronidazole for tissue invasion, Paromomycin for luminal cysts. [cite:Harrison 21e Ch 237]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.